CAR-T cell therapy for autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 65 years old
- Diagnosed with one of these conditions: lupus, Sjogren's, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that has not responded well to standard treatments
- Must have some specific lab test results that show your blood counts, liver, and kidney function are within certain limits
- Must not have active infections, certain heart or lung problems, or other cancers
- Must not have received certain other treatments recently, like other CAR-T therapies or live vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Hear when a new Sjogren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.